This week, Informa’sFinance and Accounting for Biosciencetakes place in Boston, offering pharma professionals a place to learn, network, and discuss a variety of relvant topics. These include sessions on the 2027 finance outlook; controllership concerns; SEC and FASB presentations; and sessions for pre-commercial and commercial stage biopharma finance groups.
Adam S. Mostafa,chief financial officer and head of business development at Sitryx Therapeutics, serves as chairperson of the event. He wasinterviewedbyBioXconomywhile in his prior role at X4 Pharmaceuticals.
Also presenting at the event this week are the following experts:
Gina Tracey, corporate controller at Alnylam Pharmaceuticals, recentlyspoketo the pharma finance and accounting professionals audience about talent needs in companies at various stages of growth in biotech. This week, she will join a panel on optimizing ERP systems for growth.
Justin Renz, who took on the role of chief financial officer of Zevra Therapeutics earlier thisyear, will bring his extensive biopharmaceutical financial leadership experience to the CFO Panel to discuss “Redefining Financial Leadership for Organizational Success.”
Mallory Morales, senior vice president of finance, chief accounting officer, and treasurer of Immuneering, will speak to “Preparing for Long-Term Growth: Strategies for Funding Opportunities and Operational Readiness.”Here,BioXconomyinterviewed Morales prior to her presenting at this event in 2025.
While you catch up on these past articles, look at our coverage of the event available throughout the month or in the October 27 enewsletter.
Finance & Accounting for Bioscience
Tailored to the unique needs of bioscience companies, this CPE-accredited annual forum convenes the brightest financial and accounting minds from the nation’s leading trailblazers. Hear from industry experts on high impact topics such as strategies to scale the business, creating value, emerging risks and digital transformation.
.jpg?disable=upscale&width=1200&height=630&fit=crop)